Flori­da judge dis­miss­es No­vo Nordisk law­suit over com­pound­ed semaglu­tide, but com­pa­ny plans to file again

No­vo Nordisk is plan­ning to file an amend­ed com­plaint against a Flori­da com­pound­ing phar­ma­cy it claims is il­le­gal­ly mak­ing a ver­sion of its block­buster weight-loss and di­a­betes drugs, af­ter the judge grant­ed a mo­tion to dis­miss the case last week.

In Ju­ly, No­vo filed a se­ries of law­suits against com­pound­ing phar­ma­cies, in­clud­ing three in Flori­da and one in Ten­nessee. The drug­mak­er ac­cused the them of il­le­gal­ly sell­ing drugs that they claim con­tain semaglu­tide, the pri­ma­ry in­gre­di­ent in No­vo’s block­busters We­govy, Ozem­pic and Ry­bel­sus.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER